Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?

Author： Doggrell Sheila  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.8, 2003-08, pp. : 1431-1433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention

By  

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 387-398

Bentham Science Publishers

Access to resources Recommend Favorite

Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 10, 2003-10 ,pp. : 1709-1712

Informa Healthcare

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention: Focus on the Pharmacokinetic-Pharmacodynamic Relationships of Eptifibatide

By Gilchrist I.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 703-720

Adis International

Access to resources Recommend Favorite

The use of glycoprotein IIb/IIIa receptor antagonists in percutaneous coronary intervention results in both short- and long-term benefits

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 20, Iss. 10, 2004-10 ,pp. : 7-10

Adis International

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Receptor Antagonists: A Comparative Review of Their Use in Percutaneous Coronary Intervention

By Nguyen C.M.   Harrington R.A.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 6, 2003-01 ,pp. : 423-436

Adis International

Access to resources Recommend Favorite